Drugs Used In Disorders Of Coagulation Flashcards
Unfractionated heparin (UFH)
Indirect thrombin inhibitor
Indirect thrombin inhibitors
Unfractionated heparin (UFH)
Low-molecular-weight heparin (LMWH)
Fondaparinux
Low-molecular-weight heparin (LMWH)
Indirect thrombin inhibitor
Fondaparinux
Indirect thrombin inhibitor
Antithrombin lll
Endogenous anticoagulant
Antithrombin lll
Actions
Antithrombin inhibits clotting factor proteases, especially thrombin (lla), lXa, and Xa, by forming equimolar stable complexes with them. In the absence of heparin, these reactions are slow; in presence of heparin, they are accelerated 1000-fold.
inhibits clotting factor proteases, especially thrombin (lla), lXa, and Xa, by forming equimolar stable complexes with them. In the absence of heparin, these reactions are slow; in presence of heparin, they are accelerated 1000-fold.
Antithrombin lll
Actions
LMW heparins
Enoxaparin
Dalteparin
Tinzaparin
Enoxaparin
LMW heparin
Dalteparin
LMW heparin
Tinzaparin
LMW heparin
Protamine sulfate
Usage
Antagonist of heparin
Antagonist of heparin
Protamine sulfate
Usage
Oral direct factor Xa inhibitors
Rivaroxaban
Apixaban
Apixaban
Oral direct factor Xa inhibitor
Rivaroxaban
Oral direct factor Xa inhibitor
Rivaroxaban
Apixaban
Actions
Inhibit factor Xa, in the final common pathway of clotting
Inhibit factor Xa, in the final common pathway of clotting
Rivaroxaban
Apixaban
Actions
Direct thrombin inhibitors (DTIs)
Hirudin Bivalirudin Argatroban Melagatran Dabigatran etexilate mesylate
Parenteral direct thrombin inhibitors (DTIs)
Hirudin
Lepirudin
Bivalirudin
Argatronan
Hirudin
Parenteral direct thrombin inhibitor (DTI)
Lepirudin
Parenteral direct thrombin inhibitor (DTI)
Bivalirudin
Parenteral direct thrombin inhibitor (DTI)
Argatronan
Parenteral direct thrombin inhibitor (DTI)
Oral direct thrombin inhibitor (DTI
Dabigatran etexilate mesylate
Dabigatran etexilate mesylate
Oral direct thrombin inhibitor (DTI
Fibrinolytic drugs
Streptokinase Urokinase Alteplase Reteplase Tenecteplace
Streptokinase
Fibrinolytic drug
Urokinase
Fibrinolytic drug
Alteplase
Fibrinolytic drug (Manufactured human t-PA)
Tenecteplace
Fibrinolytic drug (Manufactured human t-PA)
Reteplase
Fibrinolytic drug (Manufactured human t-PA)
Manufactured human t-PA
Alteplase
Reteplase
Tenecteplace
Fibrolytic drugs
Indications
Pulmonary embolism with hemodynamic instability
Severe deep venous thrombus
Ascending thrombophlebitis
(Acute myocardial infarction, depends on circumstances)
Pulmonary embolism with hemodynamic instability
Severe deep venous thrombus
Ascending thrombophlebitis
(Acute myocardial infarction, depends on circumstances)
Fibrolytic drugs
Indications
Antiplatelet agents
Aspirin Ticlopidine Clopidogrel Prasugrel Abciximab Eptifibatide Tirofiban Dipyridamole Cilostazol
Aspirin
Antiplatelet agent (cyclooxygenase inhibitor)
Ticlopidine
Antiplatelet agent (ADP pathway inhibitor)
Clopidogrel
Antiplatelet agent (ADP pathway inhibitor)
Prasugrel
Antiplatelet agent (ADP pathway inhibitor)
Abciximab
Antiplatelet agent (glycoprotein llb/llla inhibitor)
Eptifibatide
Antiplatelet agent (glycoprotein llb/llla inhibitor)
Tirofiban
Antiplatelet agent (glycoprotein llb/llla inhibitor)
Antiplatelet agents (glycoprotein llb/llla inhibitors)
Abciximab
Eptifibatide
Tirofiban
Antiplatelet agents (ADP pathway inhibitors)
Ticlopidine
Clopidogrel
Prasugrel
Aminocaproic acid
Clinically useful inhibitor of fibrinolysis
Clinically useful inhibitor of fibrinolysis
Aminocaproic acid